Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
FDA assigned a PDUFA goal date of June 25, 2027 FDA assigned a PDUFA goal date of June 25, 2027
FDA assigned a PDUFA goal date of June 25, 2027 FDA assigned a PDUFA goal date of June 25, 2027